ema prac semaglutide naion label update 2025 A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. https://www.medpagetoday.com/ophthalmology/generalophthalmology/115938?trw=no EMA CHMP recommends label update

GLP-1 is a peptide hormone produced by the body that has thirty amino acids

Due to one previous report outlining NAION risk and semaglutide use, the study authors relay that, in response, the American Academy of Ophthalmology has issued a press release for physicians and patients: The Academy has not recommended that patients stop using semaglutide, but rather, that patients experiencing vision loss while taking semaglutide should stop the drug and contact the physician prescribing the medication. 1 They reflect that, because of the association of semaglutide with temporary worsening of diabetic retinopathy, the increased incidence of diabetic macular edema and the concern that rapid correction of hyperglycemia could induce papillitis, physicians prescribing this medication to their patients with type II diabetes should consider a drug regimen that more gradually lowers the HbA1C level. 1 In an invited commentary on the research, also published by JAMA Ophthalmology , commentators point to a few different related studies that have already taken place, detailing their methods and outcomes

Steatohepatitis is fatty liver with inflammation, and fibrosis is the formation of scar tissue in the liver

Promotes Fat Oxidation and Metabolic Flexibility By integrating glucagon signaling with incretin effects, Retatrutide 30 mg is studied for its role in fat oxidation and substrate switching

Kim, MoonKyu Lee Diabetes, Obesity and Metabolism.2020

When incorporating Ozempic for weight loss, its essential to start with the correct dosage and adjust it over time in consultation with a healthcare provider